Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer

摘要: A year has passed since mutations of the tyrosine kinase domain epidermal growth factor receptor (EGFR) were discovered in patients with non-small cell lung cancer (NSCLC) who had dramatic clinical responses to treatment gefitinib. Additional laboratory and studies have provided further insight into biological impact EGFR culture experiments NSCLC. In vitro characterizations NSCLC lines host transfected these mutant wild-type show that most mutated are growth-inhibited by 10- 100-fold lower concentrations gefitinib erlotinib compared EGFR. treated achievable plasma undergo apoptosis rather than arrest. Retrospective NSCLC-treated reported a close association between mutations, increased chance response longer survival. This review will provide information on experiments, outcome when erlotinib, subsets whom arise.